Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Norbert Vey

Showing results (201-210 of 251) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Aline Renneville, Xavier Thomas, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Blood|August 13, 2011
Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL studyRaouf Ben Abdelali, Vahid Asnafi, Thibaut Leguay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical TrialFrançoise Huguet, Sylvie Chevret, Thibaut Leguay, et al.
Blood|October 18, 2007
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceSophie Park, Sophie Grabar, Charikleia Kelaidi, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Leukemia|February 21, 2020
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative StudySabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, et al.
Leukemia Research|April 18, 2024
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemiaGuillaume Berton, Bochra Sedaki, Erwann Collomb, et al.
Blood|August 12, 2009
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi-Boyer, Meyling Cheok, et al.
Haematologica|May 28, 2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agentsSylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, et al.
Pageof 26

Showing results (201-210 of 251) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2017
Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With NPM1 Mutation: A Study by the Acute Leukemia French Association GroupMarie Balsat, Aline Renneville, Xavier Thomas, et al.
Frontiers in Immunology|June 15, 2017
Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid LeukemiaAnne-Sophie Chretien, Cyril Fauriat, Florence Orlanducci, et al.
Blood|August 13, 2011
Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL studyRaouf Ben Abdelali, Vahid Asnafi, Thibaut Leguay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical TrialFrançoise Huguet, Sylvie Chevret, Thibaut Leguay, et al.
Blood|October 18, 2007
Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experienceSophie Park, Sophie Grabar, Charikleia Kelaidi, et al.
Blood|January 17, 2013
Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemiaEric Jourdan, Nicolas Boissel, Sylvie Chevret, et al.
Leukemia|February 21, 2020
Outcome of older (≥70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative StudySabine Kayser, Ramy Rahmé, David Martínez-Cuadrón, et al.
Leukemia Research|April 18, 2024
Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemiaGuillaume Berton, Bochra Sedaki, Erwann Collomb, et al.
Blood|August 12, 2009
TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs)Olivier Kosmider, Véronique Gelsi-Boyer, Meyling Cheok, et al.
Haematologica|May 28, 2016
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agentsSylvain Thépot, Raouf Ben Abdelali, Sylvie Chevret, et al.
Pageof 26